Wednesday, June 10, 2026

Patent intelligence · WO

WO 2019115709

INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS

granted A61K 31/ 444 A IA61P 35/ 00 A IA61P/3500
Status granted
Pipeline programs 2
Years to expiry 13
Applicant portfolio 25
Patent details — WO 2019115709
Jurisdiction
WO
Status
granted
Grant date
Jun 20, 2019
Expiration
Jun 15, 2039
CPC classes
A61K 31/ 444 A I, A61P 35/ 00 A I, A61P/3500
View on Google Patents ↗

Quick answer

WO 2019115709 (INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Jun 20, 2019. Expires Jun 15, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 444 A I, A61P 35/ 00 A I, A61P/3500

More from BASILEA PHARM INT AG [CH]

Related pharmaceutical patents in our USPTO index.

  1. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Expires May 16, 2046

    granted
  2. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Apr 11, 2046

    granted
  3. US 20260042800

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Feb 7, 2046

    granted
  4. WO 2025114603

    COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires May 31, 2045

    granted
  5. WO 2024094329

    PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires May 5, 2044

    granted
  6. CA 3268414

    MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Apr 13, 2044

    granted
  7. AU 2022323463

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Expires Feb 24, 2044

    granted
  8. AR 127448

    DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Jan 19, 2044

    granted

Frequently asked questions

What is US patent 2019115709?

WO 2019115709 (INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Jun 20, 2019. Expires Jun 15, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2019115709?

BASILEA PHARM INT AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2019115709 expire?

Our index shows an expiration date of Jun 15, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.